Companies: 10,795·Total market cap: $144.5T
Heron Therapeutics, Inc.

Heron Therapeutics, Inc.

HRTXNASDAQHealthcare● Active
$0.45
+$0.03(+6.13%)
Market Cap$71641543
P/E Ratio
52W High$2.3
52W Low$0.42
Overview

Heron Therapeutics, Inc. (HRTX) Stock Overview

Key statistics and deep links to earnings, valuation, revenue, dividends, and more.

FMP · HRTX · as of Jun 9, 2026

Key Statistics

EPS (TTM)$-0.18hrtx eps ttm · hrtx earnings per shareEarnings history
PE Ratio (TTM)hrtx pe ratio ttm · hrtx price to earningsPE Ratio deep dive
Revenue (TTM)$150.7Mhrtx revenue ttm · hrtx annual revenueFull revenue history
Dividend YieldNo Dividenddoes hrtx pay dividends · hrtx dividend yieldDividend history
Shares Outstanding166.7Mhrtx shares outstanding · hrtx floatShares outstanding history
Next EarningsAug 11, 2026Est.hrtx earnings date · hrtx next earningsEarnings history

Financial Snapshot

Full Financials
FY 2025Revenue$154.9M▲ +7.36% YoY
202320242025
heron therapeutics, inc. revenue · hrtx revenue 2025
FY 2025Net Income-$20.2M▼ 48.71% YoY
202320242025
heron therapeutics, inc. net income · hrtx profit 2025
FY 2025EPS$-0.12▼ 34.68% YoY
202320242025
hrtx eps · heron therapeutics, inc. earnings per share 2025
TTM:Revenue: $150.7MNet Income: -$30.9MEPS: $-0.18View income statement →

Analyst Ratings & Price Target

Full Forecast
SellBuy
Buy19 analystsis hrtx a buy · hrtx analyst rating
Strong Buy
0
Buy
18
Hold
1
Sell
0
Strong Sell
0
12-Month Price Target
$5.00Low
$0.45Current
$6.67Avg Target1370.46% upside
$9.00High
hrtx price target · hrtx 12 month forecast

Total: 19 · Buy rate: 94.7%

The HRTX analyst consensus is Buy, based on ratings from 19 Wall Street analysts over the past 3 months. The average 12-month price target is $6.67, representing +1370.46% upside from the current price of $0.45.

Stock Performance

Full History
1D+6.13%
1W-4.99%
1M-62.51%
3M-53.07%
YTD-65.11%
1Y-78.60%
5Y-96.76%

About Heron Therapeutics, Inc.

CEOCraig Alexander Collard
IPO DateAug 26, 1987
Employees122
CountryUS

Heron Therapeutics, Inc. is a biotechnology firm dedicated to creating innovative therapies for critical patient requirements. The company leverages its proprietary Biochronomer drug delivery platform…

what is heron therapeutics, inc. · hrtx stock overview · heron therapeutics, inc. company profile · who is heron therapeutics, inc. ceo · hrtx NASDAQ · heron therapeutics, inc. headquarters · heron therapeutics, inc. business segments

About Stock Overview & Key Data

Heron Therapeutics, Inc. (HRTX) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Aug 26, 1987. As of the latest trading session, HRTX stock price is $0.45, with a market capitalization of $71.6M. The stock has returned -78.60% over the past 12 months and -65.11% year-to-date.

According to 19 Wall Street analysts, the consensus rating for Heron Therapeutics, Inc. stock is Buy, with an average 12-month price target of $6.67. In fiscal year 2025, Heron Therapeutics, Inc. reported revenue of $154.9M and net income of -$20.2M. For detailed data — including Heron Therapeutics, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.

Frequently Asked Questions

As of the latest trading session, Heron Therapeutics, Inc. (HRTX) stock price is $0.45. The stock is traded on NASDAQ under the ticker symbol HRTX. The 52-week range is $0.42 – $2.30.

HRTX stock priceHRTX quote todaylive ticker
Data provided by Financial Modeling PrepLast updated: Jun 9, 2026Not investment advice